Navigation Links
Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
Date:1/7/2008

mong existing oral OAB treatments, according to Dr. Sand. "Watson's oxybutynin gel is an elegant topical formulation that is clear, odorless and fast drying and will offer healthcare providers a unique treatment option for OAB patients," said Dr. Sand.

The Phase 3 multi-center, double blind, placebo-controlled study evaluated the efficacy and safety of OTG in 789 patients with overactive bladder. The primary objective of the study was to demonstrate that daily treatment of a 1g dose (approximately 1 mL) of OTG for 12 weeks was superior to placebo for the relief of OAB symptoms. Changes from baseline to endpoint were calculated from a three-day patient urinary diary and included a reduction in incontinence episodes and urinary frequency, and an increase in void volume. Additionally, 216 patients participated in a 14-week, open label, safety-extension study for a total of 26 weeks. During the double-blind portion of the trial, highly statistically significant improvements relative to placebo were seen on all of these endpoints.

Secondary endpoints also included a patient assessment of incontinence-specific, quality-of-life measures using multiple validated instruments including the Incontinence Impact Questionnaire (IIQ) and the King's Health Questionnaire, which indicated a significant positive effect of OTG treatment on quality-of-life total and subscale scores at endpoint in comparison with placebo.

OTG was well tolerated in the study. No serious adverse events related to the treatment were reported. Dry mouth (6.9%) and application site pruritis (2.1%) were the only treatment-related side effects reported at levels greater than 2%. Treatment-related adverse events that resulted in study discontinuation during the double-blind period were low (1.8%) and the similar for both the treatment and placebo groups.

Phase 1 studies have demonstrated that the steady-state plasma levels of oxybutynin show little fluctuation during the 24-hour dosin
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
5. Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
6. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
9. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
10. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
11. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... HERZLIYA PITUACH, Israel , Dec. 15, 2014 ... IMNP ) announced today that its Board of Directors has ... Daniel Teper who continues as Chief Executive Officer ... Board of Directors since 2013. Immune,s new Chairman, ... represent the interest of shareholders and to continue to support ...
(Date:12/15/2014)... , December 15, 2014 Investor-Edge ... ZGNX ), Eli Lilly and Company (NYSE: ... Sanofi (NYSE: SNY ), and Novartis AG (NYSE: ... can be accessed at: http://investor-edge.com/register . On ... down 1.16%, the Dow Jones Industrial Average lost 1.79%, to ...
(Date:12/15/2014)... Government of Ghana has endorsed a project ... Terumo BCT to respond to the emerging Ebola crisis within ... system capacity to the citizens of Ghana . ... and Resilience Initiative (GERRI) is a multi-agency effort designed to: ... arrival of the Ebola epidemic , Provide new blood product ...
Breaking Medicine Technology:Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 2Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 3Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 4Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 5Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 6
... Jan. 18, 2011 BNY Mellon and The SSI Group, ... of the alliance between the two companies, SSI,s health care ... bill payment capabilities.   Under this agreement, health ... button to the screens they use in interacting with SSI,s ...
... AUSTIN, Texas, Jan. 18, 2011 Hanger Orthopedic Group, Inc. (NYSE: ... its results of operations for the quarter ended December 31, 2010, ... issue a press release announcing the results for the quarter ended ... February 9, 2011 after the close of the market. A conference ...
Cached Medicine Technology:The SSI Group to Provide Health Care Providers with BNY Mellon's Electronic Payment Solutions 2The SSI Group to Provide Health Care Providers with BNY Mellon's Electronic Payment Solutions 3Hanger Orthopedic Group, Inc. Announces Fourth Quarter 2010 Earnings Release Conference Call 2
(Date:12/17/2014)... 2014 (HealthDay News) -- Greater participation in music classes ... Researchers followed kids in the nonprofit Harmony Project, ... in Los Angeles. Over two years, children who ... how the brain processes speech and reading, compared to ... benefits of active participation in music classes occurred in ...
(Date:12/17/2014)... Doheny HealthDay Reporter , TUESDAY, ... rampant in America, and work commitment is a big reason ... sleep killer," said Dr. Mathias Basner, an assistant professor of ... Perelman School of Medicine. A time-use survey of nearly ... is the main activity exchanged for sleep. Short sleepers -- ...
(Date:12/15/2014)... Veretekk.com, Inc. announced today a strategic ... JM Ocean Avenue has secured exclusive benefit to the ... system. JM Ocean Avenue is a direct sales ... Avenue and JM International, with partial ownership coming from ... company. , “After nearly 2 decades of servicing the ...
(Date:12/15/2014)... a leading mobile app development company , custom ... which allows users to keep track of wines they ... right wine. At the center of WineMatch is ... wine information. All this information is assembled to help ... are close counterparts to one another are called Matches. ...
(Date:12/15/2014)... Steven Reinberg HealthDay Reporter ... study should reassure the millions of American women who have ... cancer. "There is no association between migraine and breast ... of medicine at Harvard Medical School. "There is no positive ... is no protective effect either." About 18 percent of ...
Breaking Medicine News(10 mins):Health News:Music Classes Boost Language Skills, Study Says 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2
... of anti-malarial drugs have made thousands of people’s life ... laws and provisions// against counterfeiters aroused – said experts. ... PLoS Medicine issue that due to counterfeiters malarial parasites ... condition. ,Facundo Fernandez, a co-author of the ...
... - Patients with an implantable cardioverter defibrillator did not ... rhythms// or death by consuming fish oil supplements, which ... to a study in the June 14 issue of ... approximately 50 percent of all death from cardiovascular disease ...
... Surgery According to the National Prostate Cancer Coalition's (NPCC) ... surgery still remains// the most common treatment choice of ... external beam radiation. ,60% of men who ... while 41% reported that they had hormone treatment with ...
... now become fond of tasting vegetables or desserts items rather ... about 200 pairs of same-sex twins. ,‘Heritability Factor’, ... beef, lamb, fish, bacon and chicken. But by contrast, environmental ... preferably. ,Mothers of 103 pairs of identical twins ...
... during pregnancy may lead to various health complications in ... anti-oxidant found naturally in foods like nuts, vegetable oil ... particularly taken with vitamin C, could help protect against ... who led a two-year study at St. Thomas' Hospital ...
... diabetes, one of the world’s leading debilitating diseases, has reached ... adults worldwide. Therefore, there is a huge demand for innovative ... ,There are two types of diabetes: ... 5% of all the cases. This type is the direct ...
Cached Medicine News:Health News:Fish Oil does not Appear to Protect Against Abnormal Heart Rhythms 2Health News:Inhaled Insulin: A New Modality for Management of Diabetes 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: